NEW YORK (GenomeWeb News) – National managed healthcare company WellPoint has revised its medical policy regarding non-invasive fetal aneuploidy screening, suggesting that it will begin covering tests such as Sequenom's MaterniT21 Plus test.

News of the change by WellPoint sent shares of Sequenom up as much as 9 percent today on the Nasdaq with the number of shares traded more than double Sequenom's average daily volume during the past three months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.